Home / Market News / $ABCL
fiscal.ai Corporate Catalyst Impact 55/100 ● neutral

Recent Analyst Rating Updates for AbCellera Biologics

Nov 13, 2026, 7:07 PM UTC · Primary ticker $ABCL

This 8-K filing discloses updated analyst ratings and price targets for AbCellera Biologics from several Wall Street firms. While most maintained 'Buy' ratings, Stifel significantly increased its price target, indicating a generally positive, though not universally uniform, outlook for the company's stock performance.

The filing details recent analyst rating updates for AbCellera Biologics, with J.P. Morgan, BMO Capital, and JonesTrading maintaining 'Buy' ratings and Stifel raising its price target from $9 to $14, also with a 'Buy' rating. This information is important for investors as analyst ratings can influence market sentiment and stock price, particularly for growth-oriented biotechnology companies. The maintained 'Buy' ratings and Stifel's increased price target suggest a generally positive outlook from these institutions, which could provide short-term upward momentum or support for the stock. However, the varying price targets indicate a range of expectations among analysts, and the impact is moderate as these are updates to existing coverage rather than new initiations or significant downgrades. For traders, this presents an opportunity to assess the current consensus and potential for price movement based on these revised expectations.

$ABCL positive Analyst rating updates and price target adjustments
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.